Is Sanofi SA halal to invest in?

As of August 2026, Sanofi SA SANO.VI is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Sanofi SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Sanofi SA using these criteria to determine its compliance status.

Can Muslims buy shares of Sanofi SA?

Muslim investors may consider investing in Sanofi SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Sanofi SA classified as HALAL?

Musaffa determines the Shariah status of Sanofi SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Sanofi SA updated?

The Shariah compliance status of Sanofi SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Sanofi SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Sanofi SA?

You can check the latest Shariah compliance status of Sanofi SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Sanofi SA SANO.VI

Last Updated: Aug 07, 12:00 AM·WBAG

SANO.VI Shariah Compliance

Screening Methodology: AAOIFI

As of August 2026, Sanofi SA is classified as halal.

HALAL

Report Source: undefined Quarter Report

Sanofi SA. Stock Analysis SANO.VI

Austria Health Care Large Cap

Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 76,493 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.